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Figure S1. Schematic representation of the strategies employed for the hermetic sealing of 
radionuclides into the cavities of carbon nanotubes (hot nanocapsules). a) Previously 
employed strategies where radionuclides (125I and 64Cu) are directly filled into carbon nanotubes1, 
2. b) Present strategy, also depicted in Fig. 1a (main text), where a non-radioactive enriched 
precursor is initially encapsulated (152Sm) and it is activated into its radioactive form by neutron 
irradiation (153Sm) in the last step. In both schematic representations, the wavy lines indicate 
radioactivity emerging from radionuclides (highlighted in the text in red).  
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Figure S2. Length distribution of 152Sm@CNT samples. a) Length distribution histogram and 
b) box plot analysis of SWNT; c) Length distribution histogram and d) box plot analysis of 
MWNT. 
 
Table S1. Descriptive analysis of the length distribution of 152Sm@CNT samples. 
 
 
 
N               
Number of 
measured CNT
Median 
(nm)
Lower 
observation 
(nm)
Lower 
adjacent 
observation 
(nm)
Q1              
25th 
percentile 
(nm)
Q3              
75th 
percentile 
(nm)
Maximum 
adjacent 
observation 
(nm)
Maximum 
observation 
(nm)
SWNT 200 199 41 41 120 397 794 3500
MWNT 200 331 40 40 192 495 932 4682
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Figure S3. External diameter distribution of 152Sm@CNT samples. a) Diameter distribution 
histogram and b) box plot analysis of SWNT; c) Diameter distribution histogram and d) box plot 
analysis of MWNT. 
 
Table S2. Descriptive analysis of the external diameter distribution of 152Sm@CNT 
samples. 
 
 
 
 
N               
Number of 
measured CNT
Median 
(nm)
Lower 
observation 
(nm)
Lower 
adjacent 
observation 
(nm)
Q1              
25th 
percentile 
(nm)
Q3              
75th 
percentile 
(nm)
Maximum 
adjacent 
observation 
(nm)
Maximum 
observation 
(nm)
SWNT 200 2.1 0.5 0.5 1.6 3.2 5.5 6.4
MWNT 200 10.7 2.5 3.4 8.8 12.8 18.2 26.2
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Figure S4. ITLC analysis of 153Sm@SWNT and 153Sm@MWNT following neutron irradiation 
of 152Sm@SWNT and 152Sm@MWNT respectively. Signals at the application point represent the 
stably encapsulated radionuclides.   
 
 
Figure S5. HRTEM images of Sm-filled SWNTs before (‘Cold’ nanocapsules) and after (‘Hot’ 
nanocapsules) irradiation.  
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Figure S6. HAADF STEM images of a 152SmCl3@SWNT showing that during electron 
microscopy observation the filling material displaces inside the SWNT. a) Initially acquired 
image and b) an image of the same area acquired after ca. 30 seconds. Displacement of the filling 
material is indicated with white bars. 
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Table S3. Neutron activated isotopes (of clinical interest) loaded onto nanocarriers. 
Nanocarrier Stable 
isotope 
Neutron 
irradiation 
time 
Neutron 
flux     
(n·cm-2·s-1) 
Reported 
radioactivitya 
Specific 
radioactivityb 
(MBq/mg) 
Ref. 
MWNT 152Sm   96 h 1.6x1014 11.37 GBq/mg 11370.0 This work 
SWNT 152Sm   96 h 1.6x1014 6.33 GBq/mg 6330.0 This work 
C82 165Ho 1 min 4.3x1014 16.13 µCi/mg 0.6 3 
MCN 165Ho   10 h 5.5x1012 208 µCi/100 µg 77.0 4 
HoIG 165Ho     0.45 h 7.0x1012 250 µCi/mg 9.3 5 
Silica NPs 165Ho     1 h 3.5x1012 213.6 µCi/mg 7.9 6 
Silica NPs 165Ho     2.2 hc 5.5x1012 129 MBq/10.7 mg 12.1  7  
Silica NPs 165Ho     2 h 5.5x1012 150 µCi/mg 5.6 8 
Silica NPs 165Ho     3 h 7.7x1012 300 µCi/mg 11.1 8 
AcAc 165Ho   13 min 5.5x1012 0.25 mCi/10 mg 0.9 9 
AcAc 165Ho     1 h 5.0×1012 600 MBq/50 mg 12.0  10 
PLLA 165Ho     1 h 1.1×1013 27.4 GBq/g 27.4 11 
MWNT: Multi-walled carbon nanotubes; SWNT: Single-walled carbon nanotubes; C82: Endohedral 
Metallofulerenes; HoIG: Holmium iron garnet; NPs: Nanoparticles; MCN: Mesoporous carbon nanoparticles; AcAc: 
NPs from acetylacetonate; PLLA: Poly-L-lactide 
NOTES:  aValues as reported in the reference provided 
bSpecific radioactivities calculated from “Reported activity” 
cIrradiation up to 18h was performed but the resulting activity is not reported 
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Figure S7. Tissue biodistribution of 153Sm@SWNT and 153Sm@MWNT (presented as %ID 
per organ). C57/Bl6 mice were i.v. injected with 200 µg of 153Sm@SWNT or 153Sm@MWNT 
(~1 MBq). The radioactivity of major organs sampled at specified time points were measured by 
γ-scintigraphy. The results are expressed as % ID/organ and presented as mean ± S.D. (n=3-4). 
 
Figure S8. Live bioluminescence images of untreated mice or mice treated with 
153Sm@SWNT or 153Sm@MWNT. B16F10-Luc tumor-bearing mice were i.v. injected with 20 
MBq in 200 µg of 153Sm@SWNT or 153Sm@MWNT on day 8 post-tumor inoculation. 
Bioluminescence signals correspond to metabolic activity of luciferase-expressing B16F10 cells 
in the lung.  
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Figure S9.  Histological examination of major organs from C57BL/6 mice at 24 h post 
injection of 153Sm@SWNT and 153Sm@MWNT. C57BL/6 mice were i.v. injected with 200 µg 
of 153Sm@SWNT or 153Sm@MWNT (~1 MBq). At 24 h post injection, heart, lung, kidney, liver, 
and spleen were excised and formalin-fixed, stained with H&E (for tissue necrosis) or Neutral 
Red (for CNT visualization). As a guide to the eye arrows point to some CNT aggregates. Scale 
bars: 50 μm. 
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Figure S10. Fit of the experimental biodistribution data (% ID) in the lung using equation 3 
described in the manuscript. Fitted parameters are ,   for 
SWNT, and ,  for MWNT. Experimental data are 
presented by circle or square dots. Lines (solid or dotted) are the fitted curve calculated using 
equation 3. 
 
 
 
 
 
 
 
 
 
 
 
153Sm@SWNT: fitted curve
153Sm@MWNT: fitted curve
153Sm@SWNT: exp. data
153Sm@MWNT: exp. data
%.ID 6160 =
101620 -= h.k 1322 -= h.m
%.ID 0280 =
101600 -= h.k 18260 -= h.m
 12 
 
Experimental Details 
 
Materials and Reagents: Chemical vapor deposition (CVD) Elicarb® SWNTs and MWNTs were 
supplied by Thomas Swan & Co. Ltd (UK) as a solid powder. The SWNT material also contains 
a fraction of few-walled carbon nanotubes, mainly double-walled. Enriched 152Sm2O3 were 
provided by CIS-Bio International-Ion Beam Applications (France). Hydrogen peroxide, 
sulphuric acid and nitric acids were purchased from Panreac AppliChem (Spain) for CNT pre-
treatment. Instant thin layer chromatography paper impregnated with silica gel (ITLC-SG) was 
obtained from Agilent Technologies (UK).  Isoflurane for anesthesia was purchased from Abbott 
(IsoFlo®, Abbott Laboratorie Ltd, UK).  
 Purification and Shortening of CNTs: Both SWNTs and MWNTs were initially treated to 
shorten the tubes, open their ends and remove carbonaceous and metallic (catalyst) impurities. 
SWNTs were exposed to a combined piranha-steam treatment, whereas MWNTs underwent a 
combined H2SO4:HNO3-steam treatment following previously reported protocols.12 
Synthesis of 152SmCl3 from 152Sm2O3: Enriched 152Sm2O3 was transformed to anhydrous 152SmCl3 
following the protocol reported for the synthesis of anhydrous SmCl3 with natural isotopic 
distribution (non-enriched).13 The synthesis of the anhydrous metal halide was performed by 
dissolution of the enriched metal oxide in HCl, followed by dehydration of the collected solid at 
240 °C under dynamic vacuum. The synthesized anhydrous 152SmCl3 is highly hygroscopic and 
was handled under an inert atmosphere.  
Filling of CNTs with 152SmCl3: Cut and purified SWNT (100 mg) or MWNT (200 mg) and 
152SmCl3 were ground together in a weight ratio 1:10 (CNTs:152SmCl3). The materials were 
ground using an agate mortar and pestle inside an argon filled glove box until the mixture 
presented a uniform color. The samples were split in smaller fractions, placed inside silica tubes 
and sealed under vacuum. The resulting silica ampoules were placed inside a horizontal tubular 
furnace and annealed for 12 h at 900 °C (SWNT) or 1200 °C (MWNT)  thus leading to the 
formation of carbon nanocapsules (closed-ended filled CNTs). The samples were recovered from 
the ampoules and the non-encapsulated material, external to the CNTs was dissolved and washed 
away. The removal of the external material was followed by UV-Vis spectroscopy of the 
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collected filtrates, until no more 152SmCl3 was detected in the washings.14 Initially the filled 
nanotubes were soaked in 200 mL of water containing 0.6 M HCl. The sample was then 
collected by filtration over a 0.2 μm polycarbonate membrane. This “pre-washing” step was 
followed by washing the sample three times in 200 mL acidic water at 80 °C for 24 h under 
constant stirring each time. The sample was collected by filtration between washings. A final 
washing step was performed using 200 mL of pure water, without the addition of HCl, whilst 
keeping the rest parameters constant. The collected solid powder was dried at 80 °C overnight.  
Neutron activation of 152Sm-filled CNTs: Vacuum sealed silica ampoules containing 30 mg of 
either 152Sm@SWNT or 152Sm@MWNT were placed in an aluminum capsule, weighed down 
with a lead-weight in a pool-type reactor (OSIRIS, CEA Saclay, France) and irradiated at a 
neutron flux of 1.6x1014 n·cm-2·s-1 for 96 h. The irradiation protocol was established according to 
equation (1):15 
A = #.%σΦ& 	(1 − 𝑒,λ-.      (1) 
where A is the predicted activity of the radioisotope produced (Bq g-1), M is the atomic mass of 
the target element (152 g mol-1 for 152Sm), Φ is the neutron flux of the reactor (1.6x1014 n cm-2s-
1), σ is the thermal neutron activation cross-section of the target isotope (206 barns for 153Sm), λ 
is the decay constant (0.693/T1/2), (T1/2 is the half life of the target isotope, which is 46.27 h for 
153Sm) and t is the irradiation time (96 h). The value of A for the given conditions can then be 
used to make a prediction of the nanotubes, by factoring in the mass of nanotubes and the 
corresponding percentage content of 152Sm that was measured before the irradiation.  
After removing the ampoules from the pool, they were allowed to cool down, removed from the 
aluminum casing, and then transferred to CIS bio International, Saclay (France) where they were 
processed in a fully sealed radioprotection hot cell. Radioactivity was measured using a dose 
calibrator (VDC 404, Veenstra Instruments, The Netherlands). The ampoules were then shattered 
and the contents (153Sm@SWNT and 153Sm@MWNT powders) were separately suspended in a 
volume of 1% Pluronic® F-127 saline (0.9 % NaCl) solution, using sonication such to produce a 
suspension with a loading of 0.5 mg/mL. The glass fragments from the broken silica ampoule 
were separated from the bulk of the suspension by sedimentation. Large aggregates of 
153Sm@CNTs were also precluded in this way. In order to transfer this product to the in vivo 
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facilities in vials, keeping within their local limits of activity handling, only a fraction of this 
suspension was then separated into a final vial, which was then shipped and arrived in a few 
days. On arrival, a sonication and a series of dilution steps were performed to ensure that the 
final dispersion injected in mice was physically stable and free of aggregates, as detailed in the in 
vivo section.  
Quantification of 152SmCl3 filling yields by ICP-MS: As a analytical validation measure, each 
carbon nanotube sample was subdivided into fractions of different sizes in the range of 1-15 mg, 
and was weighed three times on a pre-calibrated analytical balance. The samples were then 
added to a PTFE-TFM reactor in an Anton Paar Multiwave 3000, fitted with an 8SXF100 rotor. 
6 mL 65% Suprapur® nitric acid (Merck KGaA, Germany), and then 2 mL of 30% Suprapur® 
hydrogen peroxide (Merck KGaA, Germany) were dispensed from calibrated micropipettes and 
the microwave digestion was completed by applying 800 W for 40 minutes, with an initial ramp 
of 5 min. The contents of each reactor were then transferred to a polyproylene flask, followed by 
a series of washings with de-ionised water (ELGA Labwater PURELAB® Classic water 
purifying system; resistivity 18.2 MΩ/cm), and the volume was then made up to 25 mL. Two 
additional control solutions were prepared and analyzed. It was demonstrated that no impurities 
were introduced during this process using a “preparation blank,” consisting of all of the reagents 
except the nanotubes, that was passed through the microwave at the same time as the actual 
samples. It was also confirmed that all of the material that was added to the reactors was 
recovered by preparing a solution from the final washing. Prior to analysis by ICP-MS, all of the 
samples were filtered with a 33 mm 0.22 µm MILLEX ® GV PVDT filter.  
ICP-MS analysis was carried out at Cis Bio International using an ICP-MS with a quadrupole 
collision cell (PerkinElmer Sci EX ELAN® DRC II). The system check consisted of: a daily 
performance report using a standard reference solution of magnesium, indium, uranium, cerium 
and barium, with relative standard deviations (RSD) within 0.4 to 1.1% of the anticipated value. 
The sample sequence then consisted of triplicate injections of: a blank containing de-ionized 
water, the “preparation blank” and then the actual samples, separated by injections of de-ionized 
water. The quantification was performed using an external 152Sm calibration standard. The 
stability of the measurements was monitored by spiking each sample with an identical level of a 
rhodium standard of 5 ppb and this gave RSDs of less than 1%. The range of concentrations 
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chosen for the 152Sm calibration depended on the particular sample and covered the ranges of 
either 1 to 5 ppb or 1 to 30 ppb, and all of Pearson correlation coefficients R2 coefficients were 
greater than 0.9999. The results corresponding to the overall % 152Sm were then reported to one 
decimal place. 
Electron microscopy: HAADF-STEM images were acquired at 20 kV on an FEI Magellan XHR 
Scanning Electron Microscope (SEM) with the use of a specially adapted detector. HRTEM 
images were acquired on a FEI Tecnai G2 F20 microscope at 200 kV. Samples were dispersed in 
ethanol and deposited onto lacey carbon Cu grids. 153Sm@CNT were imaged after the complete 
decay of radioactivity.  EDX was carried out on a FEI Quanta SEM microscope equipped with 
an EDAX detector at 20 kV.  
Animals: All in vivo experiments were conducted under the authority of project and personal 
licenses granted by the UK Home Office and the UKCCCR Guidelines (1998). Female C57BL/6 
mice aged 6-8 weeks were purchased from Harlan (UK) and used for all in vivo studies. 
ITLC examination of 153Sm@CNTs: ITLC was performed to examine whether there was free 
153Sm present in the 153Sm@CNT suspensions (neutron irradiated 152Sm@CNT) prior to injection. 
Aliquots of 153Sm@SWNT and 153Sm@MWNT were spotted on TLC strips and then developed 
in 0.1 M ammonium acetate containing 50 mM EDTA as a mobile phase. Strips were allowed to 
dry and counted quantitatively using a cyclone phosphor detector (Packard Biosciences, UK). 
Preparation of 153Sm-CNTs for in vivo studies: The 153Sm@CNT suspensions underwent different 
dilutions to contain the appropriate radioactivity for different in vivo studies. The dilution was 
carried out by mixing the 153Sm@CNT dispersions with different amounts of non-irradiated 
152Sm@CNT suspensions (2 mg/mL in 1% Pluronic® F-127 saline). The resulting mixture was 
then sonicated for 10-15 min. Each injection dose, either for imaging, biodistribution or therapy 
studies, contained the same amount of CNT (200 µg), but possessed different radioactivity which 
are specified in their experimental sections accordingly. Injection suspensions were added with 
0.1 M EDTA (one twentieth of the injection volume) to chelate any free 153Sm. 
In vivo SPECT/CT imaging of 153Sm@CNT following i.v. injection: The biodistribution of 
153Sm@CNTs was firstly assessed by 3D whole body SPECT/CT imaging. Mice were 
anaesthetized by isoflurane inhalation during imaging. Each injection dose for 153Sm@SWNT or 
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153Sm@MWNT suspensions contained approximately 10 MBq. Injection suspensions were added 
with 0.1 M EDTA (one twentieth of the injection volume) to chelate free 153Sm. Immediately 
after injection, and at 4 h and 24 h, mice were imaged using the Nano-SPECT/CT scanner 
(Bioscan, USA). SPECT images of each mouse were taken in 24 projections over 30-40 min 
using a four-head scanner with 1.4 mm pinhole collimators. CT scans were performed at the end 
of each SPECT acquisition. All images were reconstructed by MEDISO software (Medical 
Imaging Systems), and SPECT and CT images were merged using the InVivoScopeTM software 
(Bioscan, USA). 
Pharmacokinetics and organ biodistribution of 153Sm@CNTs by γ-scintigraphy: Mice 
anaesthetized by isoflurane inhalation were injected with 153Sm@SWNT or 153Sm@MWNT 
suspensions via a tail vein. Each injection dose of 153Sm@SWNT or 153Sm@MWNT suspensions 
contained approximately 0.8 MBq. Blood was sampled from a tail vein at 5 min, 30 min, 4 h or 
24 h after injection. At 4 h and 24 h, mice were sacrificed and major organs were excised and 
weighed. To assess the excretion profiles, animals were housed individually in metabolic cages 
where the mice have free access to water but not food. Urine and feces were collected over 24 h 
after injection. The radioactivity of each sample (i.e. tissues, blood, urine or feces) was measured 
by γ-scintigraphy (LKB Wallac 1282 Compugamma, PerkinElmer) and the results were 
expressed as percentage injection dose per sample (% ID) or per g of sample (% ID/g). Collected 
organs were fixed in 10% neutral buffered formalin for histological examination. 
B16F10-Luc lung metastasis tumor model: Mice anaesthetized by isoflurane inhalation were 
injected with 5 x 105 B16F10-Luc cells in 0.2 mL of PBS via a tail vein to establish pulmonary 
melanoma metastases. Following tumor inoculation, in vivo quantitative bioluminescence 
imaging was performed on day 7, 10, 13 and 16 to monitor the tumor growth (IVIS Lumina III, 
Perkin-Elmer, UK). Mice under anesthesia were subcutaneously injected with luciferin (D-
luciferin potassium salt, Perkin-Elmer, UK) at 150 mg/kg and imaged 10 min after injection. 
Bioluminescence signals from regions of interests were measured using Living Image software 
(Perkin-Elmer, UK) and recorded as total flux (photons/sec). 
In vivo 153Sm@CNT radiotherapy studies: To determine the radiotherapeutic action of 
153Sm@SWNT and 153Sm@MWNT, B16F10-Luc tumor bearing C57BL/6 mice were randomly 
divided into three groups (n = 10): untreated, 153Sm@SWNT and 153Sm@MWNT. On day 8 post 
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tumor inoculation, mice were intravenously injected with 200 µg of 153Sm@SWNT or 
153Sm@MWNT suspensions containing approximately 20 MBq. Mice were sacrificed on day 16 
post tumor inoculation, and major organs including lung, liver, spleen, heart, and kidney were 
weighed and fixed in 10% neutral buffered formalin for histological examination. Tumor growth 
was monitored by bioluminescence imaging as described previously. The tumor growth data was 
expressed as mean ± SEM (standard error of the mean), with n denoting the number of animals. 
Significant differences were examined using one-way ANOVA followed by Tukey's multiple 
comparison test. *: p < 0.05; ***: p < 0.001  
Histological examination: Major organs excised from the mice in the biodistribution study (i.e. 
24 h post injection) and from the mice after 153Sm@CNT radiotherapy were subjected to 
histological examination. Harvested fixed organs were paraffin-embedded and sectioned for 
haematoxylin and eosin (H&E) or Neutral Red staining according to standard histological 
protocols at the Royal Veterinary College (UK). All stained sections were analysed using a Leica 
DM 1000 LED Microscope (Leica Microsystems, UK) coupled with a CCD digital camera 
(Qimaging, UK). 
References 
1. Hong, S. Y.; Tobias, G.; Al-Jamal, K. T.; Ballesteros, B.; Ali-Boucetta, H.; Lozano-
Perez, S.; Nellist, P. D.; Sim, R. B.; Finucane, C.; Mather, S. J.; Green, M. L. H.; Kostarelos, K.; 
Davis, B. G. Filled and Glycosylated Carbon Nanotubes for In Vivo Radioemitter Localization 
and Imaging. Nat. Mater. 2010, 9, 485-490. 
2. Ge, H.; Riss, P. J.; Mirabello, V.; Calatayud, D. G.; Flower, S. E.; Arrowsmith, R. L.; 
Fryer, T. D.; Hong, Y.; Sawiak, S.; Jacobs, R. M. J.; Botchway, S. W.; Tyrrell, R. M.; James, T. 
D.; Fossey, J. S.; Dilworth, J. R.; Aigbirhio, F. I.; Pascu, S. I. Behavior of Supramolecular 
Assemblies of Radiometal-Filled and Fluorescent Carbon Nanocapsules In Vitro and In Vivo. 
Chem 2017, 3, 437-460. 
3. Cagle, D. W.; Kennel, S. J.; Mirzadeh, S.; Alford, J. M.; Wilson, L. J. In Vivo Studies of 
Fullerene-Based Materials Using Endohedral Metallofullerene Radiotracers. Proc. Natl. Acad. 
Sci. U. S. A. 1999, 96, 5182-5187. 
4. Kim, J.; Luo, Z.-X.; Wu, Y.; Lu, X.; Jay, M. In-Situ Formation of Holmium Oxide in 
Pores of Mesoporous Carbon Nanoparticles as Substrates for Neutron-Activatable 
Radiotherapeutics. Carbon 2017, 117, 92-99. 
5. Munaweera, I.; Shi, Y.; Koneru, B.; Saez, R.; Aliev, A.; Di Pasqua, A. J.; Balkus, K. J. 
Chemoradiotherapeutic Magnetic Nanoparticles for Targeted Treatment of Nonsmall Cell Lung 
Cancer. Mol. Pharm. 2015, 12, 3588-3596. 
 18 
6. Munaweera, I.; Koneru, B.; Shi, Y.; Pasqua, A. J. D.; Kenneth J. Balkus, J. 
Chemoradiotherapeutic Wrinkled Mesoporous Silica Nanoparticles for Use in Cancer Therapy. 
APL Mater. 2014, 2, 113315. 
7. Di Pasqua, A. J.; Yuan, H.; Chung, Y.; Kim, J. K.; Huckle, J. E.; Li, C.; Sadgrove, M.; 
Tran, T. H.; Jay, M.; Lu, X. Neutron-Activatable Holmium-Containing Mesoporous Silica 
Nanoparticles as a Potential Radionuclide Therapeutic Agent for Ovarian Cancer. J. Nucl. Med. 
2013, 54, 111-116. 
8. Di Pasqua, A. J.; Miller, M. L.; Lu, X.; Peng, L.; Jay, M. Tumor Accumulation of 
Neutron-Activatable Holmium-Containing Mesoporous Silica Nanoparticles in an Orthotopic 
Non-Small Cell Lung Cancer Mouse Model. Inorg. Chim. Acta 2012, 393, 334-336. 
9. Di Pasqua, A. J.; Huckle, J. E.; Kim, J.-K.; Chung, Y.; Wang, A. Z.; Jay, M.; Lu, X. 
Preparation of Neutron-Activatable Holmium Nanoparticles for the Treatment of Ovarian Cancer 
Metastases. Small 2012, 8, 997-1000. 
10. Bult, W.; Varkevisser, R.; Soulimani, F.; Seevinck, P. R.; de Leeuw, H.; Bakker, C. J. G.; 
Luijten, P. R.; van het Schip, A. D.; Hennink, W. E.; Nijsen, J. F. W. Holmium Nanoparticles: 
Preparation and In Vitro Characterization of a New Device for Radioablation of Solid 
Malignancies. Pharm. Res. 2010, 27, 2205-2212. 
11. Hamoudeh, M.; Fessi, H.; Salim, H.; Barbos, D. Holmium-Loaded PLLA Nanoparticles 
for Intratumoral Radiotherapy via the TMT Technique: Preparation, Characterization, and 
Stability Evaluation after Neutron Irradiation. Drug Dev. Ind. Pharm. 2008, 34, 796-806. 
12. Kierkowicz, M.; Pach, E.; Santidrián, A.; Sandoval, S.; Gonçalves, G.; Tobías-Rossell, 
E.; Kalbáč, M.; Ballesteros, B.; Tobias, G. Comparative Study of Shortening and Cutting 
Strategies of Single-Walled and Multi-Walled Carbon Nanotubes Assessed by Scanning Electron 
Microscopy. Carbon 2018, 139, 922-932. 
13. Martincic, M.; Frontera, C.; Pach, E.; Ballesteros, B.; Tobias, G. Synthesis of Dry SmCl3 
from Sm2O3 Revisited. Implications for the Encapsulation of Samarium Compounds into Carbon 
Nanotubes. Polyhedron 2016, 116, 116-121. 
14. Martincic, M.; Pach, E.; Ballesteros, B.; Tobias, G. Quantitative Monitoring of the 
Removal of Non-Encapsulated Material External to Filled Carbon Nanotube Samples. Phys. 
Chem. Chem. Phys. 2015, 17, 31662-31669. 
15. Manual for Reactor Produced Radioisotopes, Iaea-Tecdoc-1340. Vienna, Austria, 2003, 
189-192. 
 
 
